How M&A Activity is Shaping Biotech

FDA funding cuts have perhaps created the biggest M&A opportunity in biotech history. Here’s what’s actually happening: Regulatory delays are forcing biotechs to burn through cash reserves they never planned to spend. Companies that budgeted 18 months for FDA review are now staring at 30+ month timelines with no additional runway. The math is brutal. Over 30% of public biotechs are trading below their cash value. These aren’t failed companies - they’re promising assets trapped in regulatory limbo. Smart buyers will see the opportunity. Big pharma and private equity firms are circling with $2.1 trillion in dry powder, able to scoop up innovation at fire-sale prices. What used to cost $500M in a competitive auction now goes for $200M in a distressed sale. This is a fundamental shift. Biotechs can no longer afford to go it alone through extended regulatory processes. M&A isn’t Plan B anymore - it’s Plan A for survival. The consolidation in 2025 won’t be driven by strategic vision. It’ll be driven by cash runway reality. Every biotech CEO should be stress-testing their burn rate against worst-case regulatory scenarios. Because the companies that wait too long won’t have buyers - they’ll have liquidators.

Biotech M&A activity is accelerating again, and the data behind it is important... Jefferies’ latest analysis shows a concentrated wave of strategic acquisitions over the past month: • Novartis → Avidity ($12B) • Novo Nordisk → Akero ($5.2B) • Genmab → Merus ($8B) • Pfizer → Metsera ($7.3B) • Alkermes → Avadel ($2.1B) But the story isn't the headline numbers, it’s who was positioned ahead of them. Across these takeouts, specialist investors (RTW, Avoro, RA Capital, Wellington, T. Rowe Price, Janus, Fidelity, BlackRock) captured the bulk of the value. In multiple deals, their returns exceeded $1B+. That pattern is not accidental. It reflects what buyers are actually prioritizing: 1. Late-stage clarity Programs with clean regulatory pathways, validated mechanisms, and strong pivotal-ready packages are being acquired first. 2. Payer-relevant differentiation Assets with clear access narratives, especially in cardio-metabolic, neuro, immunology, and oncology are commanding premium multiples. 3. Platform value Even in deals framed around a lead asset, buyers are explicitly paying for modality depth and pipeline leverage. This is exactly the profile of companies specialists accumulate before a takeout. For leadership teams, the signal is clear: • M&A momentum is being driven by structural needs tied to the 2028–2030 patent cliff. • Prepared companies: clinically, operationally, and commercially, are being picked up first. • “BD-ready” is now a strategic position, not an event. • The gap between prepared and unprepared teams is widening. At Kybora.com, we work with biotech executives to build exactly this level of readiness: the kind that translates scientific value into strategic value. This chart is a reminder that acquisitions don’t reward the loudest stories, they reward the companies that have already done the hard operational work.

2025 pharma's perfect storm: $25B evaporating this year. $300B more by 2030. I've followed biotech M&A for years, and what’s happening now is genuinely surprising. The patent cliff isn't coming. It's here. I saw Joanna Sadowska, PhD, EMBA "Pharma Patent Cliff" chart recently. The numbers hit different when you see them visualized: Nearly 200 drugs losing patent protection by 2030. 69 of them blockbusters - each generating over $1B annually. Here's the single biggest hit: Keytruda (pembrolizumab) - Merck's $29.5B mega-blockbuster in 2024. Core patents lapse around 2028. That's the largest absolute revenue at risk from any single drug in history. Eliquis (apixaban) follows - Bristol Myers Squibb/Pfizer's multi-billion anticoagulant. Patents ending 2026-2029 window. When a patent expires in the US, prices drop 80-90% within 12 months. Johnson & Johnson, Amgen, Novartis losing exclusivity on $25B in sales this year alone. Internal R&D can't move fast enough. So pharma is doing two things differently. They're not buying drugs anymore. They're buying time machines. Look at the pattern: • Amgen → Horizon Pharmaceuticals: $27.8B ahead of Enbrel/Prolia cliff • Bristol Myers Squibb → Karuna, Mirati, RayzeBio: offsetting Eliquis and Opdivo losses • Merck → Prometheus: $10.8B before Keytruda goes generic • Novartis → Avidity Biosciences, Inc.: $12B for RNA platform 20+ major acquisitions in 2023 alone. What changed? Pharma realized single assets don't solve multi-billion dollar cliffs. Platforms do. Technologies that generate multiple programs and absorb future shocks. And they're weaponizing AI to accelerate everything. Companies like Insilico Medicine are collapsing drug discovery timelines: Traditional discovery: 5+ years, hundreds of millions. AI-driven discovery: 18 months, $2.6M. Insilico took a novel IPF drug from target identification to Phase 1 in under 30 months. That's not incremental improvement. That's a paradigm shift. Here's why this matters: Historically, pharma earnings multiples compress 12-24 months before major patent losses. Investors punish stocks because replacement takes too long. But with AI accelerating innovation hit rates and platform M&A providing repeatable pipelines - is there less sensitivity now? Merck is already proving this. Keytruda QLEX (subcutaneous version) to extend market life + Prometheus pipeline + @Acceleron assets. The correlation to watch: AI acceleration → higher hit rates → shorter replacement gaps → less cliff sensitivity. We're witnessing a shift from single-product dependency to portfolio regeneration systems. The next 24 months will reshape biopharma for the next decade. Patent cliffs are the forcing function. Platform capacity + AI acceleration = the solution. The question isn't "will the cliff hit?" It's already here. The real question: "Can innovation velocity finally outrun patent expiration?" For the first time in pharma history, we might actually see the answer be yes.

Biotech’s New Buyers Are Not Who You Think 🚨 The biggest shift in biotech M&A isn’t the deals. It’s the buyers. For decades, the acquirer list was predictable. Not anymore. 💥 Who’s moving in: → Private Equity: KKR just dropped $3B on royalty rights for rare disease drugs. Blackstone Life Sciences is building an entire late-stage asset portfolio for cash flow. → Sovereign Wealth Funds: Saudi’s PIF backed a $500M cell therapy JV. Abu Dhabi’s Mubadala quietly took stakes in 3 APAC bio-manufacturers in 12 months, health sovereignty at work. → APAC Strategics: Japan’s Astellas, Singapore’s Temasek-backed ventures, and South Korea’s SK Bioscience are picking up clinical assets the US can’t or won’t touch due to geopolitics. → Royalty Funds: $14B+ projected deal flow this year, growing 45% CAGR, turning predictable drug revenues into tradable financial assets. 📌 Why it matters: ⭐ Different buyers = different diligence, timelines, and valuation math ⭐ PE chases cash flow now; sovereigns bet on national capability in 10 years ⭐ Many move faster than Pharma — no FDA pipeline bottlenecks This is the new map for exits, partnerships, and capital. If you’re only selling to Pharma, you’re playing on half the field. DM me if you want a deeper dive. #Biotech #MergersAndAcquisitions #VentureCapital #PrivateEquity #LifeSciences Ron Chiarello Consulting

When you can't match the bid, Better Call Saul. Remember when I wrote about pharma M&A being like chess, where smart players think several moves ahead? Player One agreed to buy an obesity biotech for $4.9 billion in September, but Player Two offered $6.5 billion last month, and now Player One is suing twice instead of raising their bid. They filed in Delaware court claiming breach of contract, then federal court claiming antitrust violations, arguing that Player Two’s acquisition would reinforce their obesity duopoly with the market share leader. The target called it what it is: trying to litigate their way to a lower price. *** My assumption as to what is happening beneath the legal process. Player One knows they need obesity assets to fill pipeline gaps while investors are watching, but that extra $1.6 billion matters when you're already stretched on R&D spending. Player Two has deeper pockets for this fight because they already dominate the obesity market and adding this target only strengthens their competitive moat. The litigation creates friction and buys time while making the target's board nervous enough that they might accept the lower offer just to avoid months of legal battles. But when you sue instead of raising your bid, you're broadcasting exactly where your financial ceiling is. The target gave Player One five days to counter after receiving the competing offer, and Player One's response was to hire lawyers instead of investment bankers. The deadline hits Tuesday, the same morning Player One reports earnings, which gives them the perfect platform to either announce a higher bid or explain to investors why walking away demonstrates financial discipline. They'll likely walk and frame it as prudent capital allocation, but everyone in the industry knows that when Player Two put $1.6 billion more on the table, Player One brought lawyers instead of cash. In M&A, this scenario shows who really wants the asset versus who is trying to save the game. #biopharma #mergersandacquisitions #strategy

My thoughts coming out of Jefferies week in London... H1 2022 – H1 2025 were very tough for biotech, life sciences as well as the tools and technology companies that support them.  I have heard from several industry veterans that “this is the toughest I have seen it in my (30) years in life sciences.” But there are reasons for optimism looking to 2026.  My recruiter, banker, VC and lawyer friends are telling me they are seeing increased investor interest, deal volumes, transactions and recruiting happening in the life sciences space including cell and gene therapy.   They are usually the leading indicators of a return to growth. Since June, things have started to pick up which is giving everyone optimism that we are coming out of the bottom of the cycle. Below are 10 reasons to be optimistic about 2026: 1.     Pharma faces a $236B patent cliff in the next 5 years which will fuel M&A 2.     Pharma M&A has topped $150B in 2025 (so far) 3.     The XBI is back over 100 and up 47% in the last 6 months 4.     Pharma has done >$18B worth of life sciences deals from China alone 5.     In the US alone there is >$300B in dry powder in life sciences VC coffers, we can add another 30-50% to get the global total 6.     Most cyclical economic downturns last only 12-24 months and this one has been going for longer than 36 months depending on how you count it 7.     Two rate cuts since September (-50 bps) with at least one additional rate cut in 2026 expected – making sitting on cash more expensive and risky, long dated assets (like life sciences) more attractive 8.     Life sciences tools companies like Repligen, Thermo Fisher, Danaher and Sartorius all reported good earnings and are forecasting a return to growth in 2026 9.     Cell and gene therapy alone has raised over $7.4B this year in private and public financings and M&A 10. At Ori Biotech we have recently announced our 13th partner (thank you Seattle Children's Research Institute) and we expect to hit 15 by the end of 2025 – CGT biotechs, AMCs, Big Pharma and CDMOs are investing in new technology to invest in CGT 2.0 Generalist investors aren’t fully back in life sciences but they are looking for exposure to what is working.  I am hopeful that 2026 will bring what we had hoped for in 2025 until Trump started sword rattling in Q2 ’25 with Tariffs etc which killed risk taking in the H1 ’25. Comment below on what you are seeing and hearing post Jefferies last week. Bring on #JPM2026 and a return to growth for the life sciences industry in 2026! #celltherapy #cellandgenetherapy #biotechnology